Deloitte and Oracle have transformed the legacy data systems of the world’s largest independent global dermatology company, Galderma, through the implementation of Deloitte SuperLedger™, a platform built on Oracle Cloud.
Galderma was founded four decades ago as a joint venture between L’Oreal and Nestlé, but after Nestlé divested, and then a private equity consortium acquired Galderma in 2019, the imperative to rapidly transform its application environment and exit the Nestlé infrastructure became more pressing.
Though the business was posting growth, Galderma lacked the integrated platform needed to support its ambition of becoming the leading dermatology company in the world. It required a solution that would rapidly unify systems across geographies and lines of business, unlocking and analysing vast amounts of data that would facilitate innovation.
In a webinar hosted by Swiss publication Finanz und Wirtschaft, Thomas Dittrich, Galderma CFO, explained: “Galderma decided to pursue an end-to-end transformation that implemented integrated business planning, freed up resources, and pooled what could not be entirely automated and streamlined into shared services, enabling the introduction of new ones.”
Deloitte UK and Deloitte Switzerland enabled the company to achieve this goal through implementing SuperLedger™, a platform built on Oracle Cloud, to bridge disparate systems and enable Galderma to standardise operations and deploy modern analytic tools that freed the company to focus on its highly competitive core business.
The platform now aggregates and extracts data from multiple ERPs spanning India to South America to Russia, empowering Galderma’s finance leaders with a single source of truth for all financial reporting and analysis, as well as real-time visibility into business performance across all those geographies.
Deloitte led the digital transformation project, upgrading Oracle E-Business Suite software to Oracle Fusion Cloud ERP, EPM and supply chain management components for Galderma’s North America operations, which constitute a significant part of the company’s overall revenue.
The transformation has already spurred a boom in innovation across Galderma’s science-based portfolio which includes iconic brands such as Cataphil, Restylane, and Differin, and puts the company within striking distance of becoming the leading dermatology company in the world.